Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can …
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced …
Cohort 1:Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant ovarian cancer. Cohort 2:Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant endometrial cancer.
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD). We would like to rely on NMDP IRB as the IRB of record for this study.
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies. We would like to rely on WCG as the IRB of record for this study.
Primary Objectives Evaluate utility of FES PET/CT to detect estrogen receptor (ER+) uterine cancer lesions in patients with recurrent or metastatic uterine cancer Secondary Objectives Evaluate utility of FES PET/CT compared to standard axial cross-sectional imaging and/or FDG PET/CT when available to establish tumor heterogeneity and staging Correlate FES uptake …
This is a Phase Ib/II study in participants with advanced liver cancers. Cohort 1 - participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible …
mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells …
